Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Mon, February 16, 2009Fri, February 13, 2009Thu, February 12, 2009Wed, February 11, 2009Tue, February 10, 2009MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full-Year Financial Results
Published in Health and Fitness on Thursday, February 19th 2009 at 9:12 GMT, Last Modified on 2009-02-19 09:13:25 by Market Wire
WESTLAKE, Texas--([ BUSINESS WIRE ])--MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to announce its financial results for the 2008 fourth quarter and full year on Thursday, March 5, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2008 fourth quarter and full year.
To listen live to the call, dial 1-800-813-8504 or 1-660-422-4526. A replay of the call will be available starting at approximately 11 a.m. on March 5 through 5 p.m. on March 12, 2009. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and enter the conference ID # 86529116.
A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, [ www.middlebrookpharma.com ]. A replay of the webcast will be available starting at approximately 11 a.m. on March 5 through 5 p.m. on April 3, 2009.
About MiddleBrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS®, which enables delivery in rapid bursts, or pulsatile delivery, of certain drugs. We are currently developing a portfolio of anti-infective products utilizing our PULSYS® technology. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing for antibiotics that have been used and trusted by physicians and patients for decades which we believe will result in improved patient dosing convenience and compliance. MiddleBrook currently markets KEFLEX®, the immediate-release brand of cephalexin, and will begin promoting MOXATAG™ – the first and only FDA-approved once-daily amoxicillin – to health care professionals nationwide on March 16, 2009. For more information about MiddleBrook, please visit [ www.middlebrookpharma.com ].
